文献速递癫痫

左乙拉西坦与拉莫三嗪作为女性特发性全面性癫痫患者一线抗癫痫药物的比较

Levetiracetam vs Lamotrigine as First-Line Antiseizure Medication in Female Patients With Idiopathic Generalized Epilepsy.
PubMed 文献 · JAMA Neurol · 2023-01-01

这项多中心回顾性队列研究纳入543例育龄期特发性全面性癫痫女性患者,比较左乙拉西坦与拉莫三嗪作为初始单药治疗的有效性和安全性。经IPTW校正后,左乙拉西坦与治疗失败风险降低相关(HR 0.77,95%CI 0.59-0.99,P=0.04),但分层后仅在青少年肌阵挛癫痫中确认优势(HR 0.47,95%CI 0.32-0.68,P<0.001)。左乙拉西坦不良反应更常见(28.2% vs 18.1%),两种药物保留率相似。

要点

  • 左乙拉西坦与治疗失败风险降低相关(IPTW校正HR 0.77,95%CI 0.59-0.99,P=0.04)。
  • 分层后左乙拉西坦优势仅见于青少年肌阵挛癫痫(HR 0.47,95%CI 0.32-0.68,P<0.001)。
  • 左乙拉西坦不良反应更常见(88/312例,28.2% vs 42/231例,18.1%)。

核心结论

  • 在青少年肌阵挛癫痫女性患者中,左乙拉西坦可作为初始替代单药治疗。
  • 其他特发性全面性癫痫综合征的最佳替代抗癫痫药物仍需进一步研究。

研究设计与样本

  • 多中心回顾性比较有效性队列研究,分析1994年至2022年随访数据。
  • 患者来自4个国家的22个成人及儿童癫痫中心。
  • 纳入育龄期女性,按国际抗癫痫联盟(2022)标准诊断为特发性全面性癫痫,并以左乙拉西坦或拉莫三嗪作为初始单药治疗。
  • 共纳入543例患者,左乙拉西坦组312例(57.5%),拉莫三嗪组231例(42.5%)。
  • 用药时中位年龄17岁(IQR 15-21),中位随访60个月(IQR 24-108)。

主要发现

  • 经IPTW校正的Cox模型显示,左乙拉西坦与治疗失败风险降低相关(HR 0.77,95%CI 0.59-0.99,P=0.04)。
  • 分层分析显示,左乙拉西坦的优势仅在青少年肌阵挛癫痫中确认(IPTW校正HR 0.47,95%CI 0.32-0.68,P<0.001),其他综合征中无显著差异。
  • 左乙拉西坦组不良反应更常见(88/312例,28.2% vs 42/231例,18.1%)。
  • 两种药物随访期间保留率相似(IPTW校正HR 0.91,95%CI 0.65-1.23,P=0.60)。

临床怎么用

  • 作者认为,在青少年肌阵挛癫痫女性患者中可考虑左乙拉西坦作为初始替代单药治疗。
  • 其他特发性全面性癫痫综合征的最佳替代抗癫痫药物选择仍需进一步研究。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: After the recent limitations to prescribing valproate, many studies have highlighted the challenging management of female patients of reproductive age with idiopathic generalized epilepsy (IGE). However, no study, to the authors' knowledge, has addressed the comparative effectiveness of alternative antiseizure medications (ASMs) in these patients. OBJECTIVE: To compare the effectiveness and safety of levetiracetam and lamotrigine as initial monotherapy in female patients of childbearing age with IGE. DESIGN, SETTING, AND PARTICIPANTS: This was a multicenter, retrospective, comparative effectiveness cohort study analyzing data from patients followed up from 1994 to 2022. Patients were recruited from 22 primary, secondary, and tertiary adult and child epilepsy centers from 4 countries. Eligible patients were female individuals of childbearing age, diagnosed with IGE according to International League Against Epilepsy (2022) criteria and who initiated levetiracetam or lamotrigine as initial monotherapy. Patients were excluded due to insufficient follow-up after ASM prescription. EXPOSURES: Levetiracetam or lamotrigine as initial monotherapy. MAIN OUTCOMES AND MEASURES: Inverse probability of treatment weighting (IPTW)-adjusted Cox proportional hazards regression was performed to compare treatment failure (TF) among patients who received levetiracetam or lamotrigine as initial monotherapy. RESULTS: A total of 543 patients were included in the study, with a median (IQR) age at ASM prescription of 17 (15-21) years and a median (IQR) follow-up of 60 (24-108) months. Of the study population, 312 patients (57.5%) were prescribed levetiracetam, and 231 (42.5%) were prescribed lamotrigine. An IPTW-adjusted Cox model showed that levetiracetam was associated with a reduced risk of treatment failure after adjustment for all baseline variables (IPTW-adjusted hazard ratio [HR], 0.77; 95% CI, 0.59-0.99; P = .04). However, after stratification according to different IGE syndromes, the higher effectiveness of levetiracetam was confirmed only in patients with juvenile myoclonic epilepsy (JME; IPTW-adjusted HR, 0.47; 95% CI, 0.32-0.68; P < .001), whereas no significant differences were found in other syndromes. Patients treated with levetiracetam experienced adverse effects more frequently compared with those treated with lamotrigine (88 of 312 [28.2%] vs 42 of 231 [18.1%]), whereas the 2 ASMs had similar retention rates during follow-up (IPTW-adjusted HR, 0.91; 95% CI, 0.65-1.23; P = .60). CONCLUSIONS AND RELEVANCE: Results of this comparative effectiveness research study suggest the use of levetiracetam as initial alternative monotherapy in female patients with JME. Further studies are needed to identify the most effective ASM alternative in other IGE syndromes.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Cerulli Irelli E, Cocchi E, Morano A, et al. Levetiracetam vs Lamotrigine as First-Line Antiseizure Medication in Female Patients With Idiopathic Generalized Epilepsy. JAMA Neurol. 2023. PMID: 37782485. doi:10.1001/jamaneurol.2023.3400

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。